

393

BSE LTD			
ACKNOWLEDGEMENT			
Acknowledgement No	: 2905202607524927	Date & Time	: 29/05/2026 06:33:29 PM
Scrip Code	: 512101		
Entity Name	: TriochemProducts Limited		
Compliance Type	: Regulation 33(3)-Integrated Finance Ind AS		
Quarter / Period	: 31/03/2026		
Mode	: XBRL E-Filing		

General information about company	
Scrip code*	512101
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE331E01013
Name of company	TriochemProducts Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	29-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	22-05-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable.
Start date and time of board meeting	29-05-2026 15:00
End date and time of board meeting	29-05-2026 17:50
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	24-10-2025
Indicate Company website link for updated RPT policy of the Company	<a href="https://www.triochemproducts.com/uploads/Investor-relations/pdfs/related-party-transactions-ver04-262-4228.pdf">https://www.triochemproducts.com/uploads/Investor-relations/pdfs/related-party-transactions-ver04-262-4228.pdf</a>
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	Yes

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-01-2026	01-04-2025
Date of end of reporting period		31-03-2026	31-03-2026
Whether results are audited or unaudited		Unaudited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	0	0
	Other income	12.77	86.45
	<b>Total income</b>	<b>12.77</b>	<b>86.45</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	11.19	52.91
(e)	Finance costs	7.93	7.93
(f)	Depreciation, depletion and amortisation expense	0	4.66
<b>(g)</b>	<b>Other Expenses</b>		
1	Other Expenses	11.29	85.8
	<b>Total other expenses</b>	<b>11.29</b>	<b>85.8</b>
	<b>Total expenses</b>	<b>30.41</b>	<b>151.3</b>
<b>3</b>	<b>Total profit before exceptional items and tax</b>	<b>-17.64</b>	<b>-64.85</b>
4	Exceptional items	1116.65	1116.65
<b>5</b>	<b>Total profit before tax</b>	<b>1099.01</b>	<b>1051.8</b>
<b>6</b>	<b>Tax expense</b>		
7	Current tax	214.35	214.35
8	Deferred tax	52.09	40.38
<b>9</b>	<b>Total tax expenses</b>	<b>266.44</b>	<b>254.73</b>
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>11</b>	<b>Net Profit Loss for the period from continuing operations</b>	<b>832.57</b>	<b>797.07</b>
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
<b>14</b>	<b>Net profit (loss) from discontinued operation after tax</b>	<b>0</b>	<b>0</b>
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>16</b>	<b>Total profit (loss) for period</b>	<b>832.57</b>	<b>797.07</b>
17	<a href="#">Other comprehensive income net of taxes</a>	-111.8	-98.95
<b>18</b>	<b>Total Comprehensive Income for the period</b>	<b>720.77</b>	<b>698.12</b>
<b>19</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
<b>20</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
<b>21</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	24.5	24.5
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve		2040.3
<b>23</b>	<b>Earnings per share</b>		

19

<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	339.83	325.34
	Diluted earnings (loss) per share from continuing operations	339.83	325.34
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>iii</b>	<b>Earnings per equity share (for continuing and discontinued operations)</b>		
	Basic earnings (loss) per share from continuing and discontinued operations	339.83	325.34
	Diluted earnings (loss) per share from continuing and discontinued operations	339.83	325.34
24	Debt equity ratio		Textual Information( 1)
25	Debt service coverage ratio		Textual Information( 2)
26	Interest service coverage ratio		Textual Information( 3)
<b>27</b>	<b>Disclosure of notes on financial results</b>	<b>Textual Information(4)</b>	

## Text Block

Textual Information(4)

- 1) The above audited financial results of the Company for the quarter and year ended 31st March 2026 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 29.05.2026. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.
- 2) The audited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.
- 4) The Board of Directors of the Company, at its meeting held on 24th October 2025, approved the proposal for the sale of certain immovable properties, plant & machinery, and investment properties situated in Maharashtra. The proposed transaction constituted a Material Related Party Transaction in accordance with the provisions of Section 188 of the Companies Act, 2013 and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the approval of the shareholders through Postal Ballot was obtained on 13th December 2025. Subsequently, the sale of the aforesaid assets was completed in multiple tranches as under:  
 Land and one investment property - 19th January 2026  
 Another investment property - 30th January 2026  
 Remaining investment properties - 5th February 2026  
 The assets sold had an aggregate Written Down Value (WDV) of Rs. 56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounted to approximately Rs. 672.05 lakhs in respect of property, plant & machinery and Rs. 501.15 lakhs (net of transfer expense amounting to Rs. 8.85 lakhs) in respect of investment properties. Resultant gain of Rs. 1,116.65 lakhs has been recognised as an exceptional items in current quarter result. The sale consideration was received entirely in cash.  
 The transaction was undertaken on an arm's length basis and in the ordinary course of business, with the objective of monetising non-core assets of the Company. The proceeds from the sale are proposed to be utilised towards funding new business ventures and other strategic initiatives of the Company.
- 5) The figure for quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between audited figures of the full financial year and the reviewed year-to-date figures up to the third quarter of the relevant financial year.
- 6) The Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		31-03-2026
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
<b>Assets</b>		
<b>1</b>	<b>Non-current assets</b>	
	Property, plant and equipment	
	Capital work-in-progress	
	Investment property	
	Goodwill	
	Other intangible assets	
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	<b>Non-current financial assets</b>	
	Non-current investments	788.76
	Trade receivables, non-current	
	Loans, non-current	
	<b>Other non-current financial assets</b>	
1		
2		
3		
4		
5		
	<b>Details of other non-current financial assets</b>	
	<b>Total of other non-current financial assets</b>	
	<b>Total non-current financial assets</b>	<b>788.76</b>
	Deferred tax assets (net)	
	<b>Other non-current assets</b>	
1		
2		
3		
4		
5		
	<b>Details of other non-current assets</b>	
	<b>Total of other non-current assets</b>	
	<b>Total non-current assets</b>	<b>788.76</b>
<b>2</b>	<b>Current assets</b>	
	Inventories	
	<b>Current financial asset</b>	
	Current investments	
	Trade receivables, current	
	Cash and cash equivalents	1172.97
	Bank balance other than cash and cash equivalents	
	Loans, current	
	<b>Other current financial assets</b>	
1	Other current financial assets	0.5
2		
3		
4		
5		

<b>Details of other current financial assets</b>		
<b>Total of Other current financial assets</b>		<b>0.5</b>
<b>Total current financial assets</b>		<b>1173.47</b>
Current tax assets (net)		0.33
<b>Other current assets</b>		
1	Other current assets	125.3
2		
3		
4		
5		
<b>Details of other current assets</b>		
<b>Total of other current assets</b>		<b>125.3</b>
<b>Total current assets</b>		<b>1299.1</b>
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
<b>Total assets</b>		<b>2087.86</b>
<b>Equity and liabilities</b>		
<b>1 Equity</b>		
<b>Equity attributable to owners of parent</b>		
Equity share capital		24.5
Other equity		2040.3
<b>Total equity attributable to owners of parent</b>		<b>2064.8</b>
Non controlling interest		
<b>Total equity</b>		<b>2064.8</b>
<b>2 Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Non-current financial liabilities</b>		
Borrowings, non-current		
<b>Trade Payables, non-current</b>		
(A) Total outstanding dues of micro enterprises and small enterprises		
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		
<b>Total Trade payable</b>		
<b>Other non-current financial liabilities</b>		
1		
2		
3		
4		
5		
<b>Details of other non-current financial liabilities</b>		
<b>Total of other non-current financial liabilities</b>		
<b>Total non-current financial liabilities</b>		
Provisions, non-current		
Deferred tax liabilities (net)		19.94
Deferred government grants, Non-current		
<b>Other non-current liabilities</b>		
1		
2		
3		
4		
5		
<b>Details of other non-current liabilities</b>		
<b>Total of other non-current liabilities</b>		
<b>Total non-current liabilities</b>		<b>19.94</b>
<b>Current liabilities</b>		
<b>Current financial liabilities</b>		
Borrowings, current		

23

	<b>Trade Payables, current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	2.95
	<b>Total Trade payable</b>	<b>2.95</b>
	<b>Other current financial liabilities</b>	
1	Other current financial liabilities	0.17
2		
3		
4		
5		
	<b>Details of other current financial liabilities</b>	
	<b>Total of other current financial liabilities</b>	<b>0.17</b>
	<b>Total current financial liabilities</b>	<b>3.12</b>
	<b>Other current liabilities</b>	
1		
2		
3		
4		
5		
	<b>Details of other current liabilities</b>	
	<b>Total of other current liabilities</b>	
	Provisions, current	
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	<b>Total current liabilities</b>	<b>3.12</b>
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	<b>Total liabilities</b>	<b>23.06</b>
	<b>Total equity and liabilities</b>	<b>2087.86</b>
	<b>Disclosure of notes on assets and liabilities</b>	Textual Information(1)

**Text Block**

Textual Information(1)

- 1) The above audited financial results of the Company for the quarter and year ended 31st March 2026 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 29.05.2026. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon.
- 2) The audited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.
- 4) The Board of Directors of the Company, at its meeting held on 24th October 2025, approved the proposal for the sale of certain immovable properties, plant & machinery, and investment properties situated in Maharashtra. The proposed transaction constituted a Material Related Party Transaction in accordance with the provisions of Section 188 of the Companies Act, 2013 and Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the approval of the shareholders through Postal Ballot was obtained on 13th December 2025. Subsequently, the sale of the aforesaid assets was completed in multiple tranches as under:  
 Land and one investment property - 19th January 2026  
 Another investment property - 30th January 2026  
 Remaining investment properties - 5th February 2026  
 The assets sold had an aggregate Written Down Value (WDV) of Rs. 56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounted to approximately Rs. 672.05 lakhs in respect of property, plant & machinery and Rs. 501.15 lakhs (net of transfer expense amounting to Rs. 8.85 lakhs) in respect of investment properties. Resultant gain of Rs. 1,116.65 lakhs has been recognised as an exceptional items in current quarter result. The sale consideration was received entirely in cash.  
 The transaction was undertaken on an arm's length basis and in the ordinary course of business, with the objective of monetising non-core assets of the Company. The proceeds from the sale are proposed to be utilised towards funding new business ventures and other strategic initiatives of the Company.
- 5) The figure for quarter ended March 31, 2026 and March 31, 2025 are the balancing figures between audited figures of the full financial year and the reviewed year-to-date figures up to the third quarter of the relevant financial year.
- 6) The Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

<b>Other Comprehensive Income</b>			
	Date of start of reporting period	01-01-2026	01-04-2025
	Date of end of reporting period	31-03-2026	31-03-2026
	Whether results are audited or unaudited	Unaudited	Audited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		
3	Amount of items that will be reclassified to profit and loss		
1	Items that will not be reclassified to profit or Loss	-130.76	-115.79
2	Income tax relating to items that will not be reclassified to profit or loss	18.96	16.84
	Total Amount of items that will be reclassified to profit and loss	-111.80	-98.95
4	Income tax relating to items that will be reclassified to profit or loss		
		0.00	0.00
5	Total Other comprehensive income	-111.80	-98.95

<b>Cash flow statement, indirect</b>		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
<b>Part I</b>	Blue color marked fields are non-mandatory.	
<b>1</b>	<b>Statement of cash flows</b>	
	Cash flows from used in operating activities	
	Profit before tax	1051.8
<b>2</b>	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	0
	Adjustments for decrease (increase) in inventories	0
	Adjustments for decrease (increase) in trade receivables, current	0
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	20.8
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	9.25
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	-14.16
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-0.37
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	4.66
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	-6.37
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	8.64
	Adjustments for interest income	8.91
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	2.81
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-1139.8
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	<b>-1140.73</b>
	<b>Net cash flows from (used in) operations</b>	<b>-88.93</b>
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	198.51
	Other inflows (outflows) of cash	0.04
	<b>Net cash flows from (used in) operating activities</b>	<b>-287.4</b>
<b>3</b>	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0

27

	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	678.16
	Purchase of property, plant and equipment	0
	Proceeds from sales of investment property	494.04
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	180
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	8.64
	Interest received	8.91
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-0.04
	<b>Net cash flows from (used in) investing activities</b>	<b>1369.71</b>
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	0
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	<b>Net cash flows from (used in) financing activities</b>	<b>0</b>
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>1082.31</b>
<b>5</b>	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0
	<b>Net increase (decrease) in cash and cash equivalents</b>	<b>1082.31</b>
	Cash and cash equivalents cash flow statement at beginning of period	90.66
	<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>1172.97</b>

**Format for Disclosure of Related Party Transactions (applicable only for h**

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In c are c of th  Oper balar
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								
1	Triochem Products Limited	AAACT2202J	G Amphray Laboratories	ABCFG7108E	Key managerial person is partner	Sale of goods or services		77.88	Approved	77.88	24-05-2025	19.47	0

2	Triochem Products Limited	AAACT2202J	G Ampray Laboratories	ABCFG7108E	Key managerial person is partner	Sale of fixed assets		817.25	Approved	817.25	24-10-2025	817.22	0
3	Triochem Products Limited	AAACT2202J	Rajesh Ramu Deora	ADXP0928Q	Director of the Company	Loan		50	Approved	50	24-05-2025	30	0
4	Triochem Products Limited	AAACT2202J	Rajesh Ramu Deora	ADXP0928Q	Director of the Company	Sale of fixed assets		375	Approved	375	24-10-2025	375	0
Total value of transaction during the reporting period											1241.69		

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Kanu Doshi Associates LLP	Yes	31-12-2028

**Format for Disclosing Outstanding Default on Loans and Debt Securities**

Sr. No.	Particulars	Amount	Remarks
1.	Loans / revolving facilities like cash credit from banks / financial institutions		
A	Total amount outstanding as on date	0	
B	Of the total amount outstanding, amount of default as on date	0	
2.	Unlisted debt securities i.e. NCDs and NCRPS		
A	Total amount outstanding as on date	0	
B	Of the total amount outstanding, amount of default as on date	0	
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	0	



Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including c to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be rep
3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investm
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or ii transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party m manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed s
6. In case of a multi-year related party transaction:
  - a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction a
  - b. The value of the related party transaction ratified by the audit committee shall be disclosed in the column "Value of the related party transaction ratified by the auc
  - c. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reportir
7. "Cost" refers to the cost of borrowed funds for the listed entity. 8. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related partie

commitments,

orted once.

ents made or given by the listed banks.

vestment) with a single party shall be disclosed separately and there should be no clubbing or netting of

ay be aggregated for the reporting period and purchase transactions may also be disclosed in a similar  
eparately, without any netting off.

s approved by the audit committee”.

dit committee”.

ig period”.

s, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.

Home

Validate

Amount in (Lakhs)

**Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)**


Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary	

Add

Delete

1	Triochem Products Limited	AAACT2202J	G Amphray Laboratories	ABCFG7108E	Key managerial person is partner	Sale of goods or services
2	Triochem Products Limited	AAACT2202J	G Amphray Laboratories	ABCFG7108E	Key managerial person is partner	Sale of fixed assets
3	Triochem Products Limited	AAACT2202J	Rajesh Ramu Deora	ADXP0928Q	Director of the Company	Loan
4	Triochem Products Limited	AAACT2202J	Rajesh Ramu Deora	ADXP0928Q	Director of the Company	Sale of fixed assets

**Total value of transaction during the reporting period**



Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction	
						Opening balance	Closing balance

	77.88	Approved	77.88	24-05-2025	19.47	0.00	0.00
	817.25	Approved	817.25	24-10-2025	817.22	0.00	0.00
	50.00	Approved	50.00	24-05-2025	30.00	0.00	0.00
	375.00	Approved	375.00	24-10-2025	375.00	0.00	0.00
					1241.69		

37

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subs undertaken.

In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-co			
Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured

				Loan	0.00%	Two Month	Unsecured

38

subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was

Corporate deposits, advances or investments

Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
	<p>This is to inform you that Disclosures of the Related Party Transaction on a consolidated basis under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018 is not applicable to our Company.</p> <p>As per Regulation 15(2) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, the compliance with corporate governance provisions as specified in regulations 17, [17A,] 18, 19, 20, 21,22, 23, 24, 24A, 25, 26, 27 and clauses (b) to (i) [and (t)] of sub-regulation (2) of regulation 46 and para C, D and E of Schedule V shall not apply, in respect of -</p> <p>The listed entity having paid up equity share capital not exceeding rupees ten crore and net worth not exceeding rupees twenty-five crore, as on the last day of the previous financial year.</p> <p>Further, we would like to clarify that our claiming exemption under Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the compliance with the Corporate Governance provision shall not apply to listed entities having Paid up equity share capital not exceeding Rs.10 Crores and Net worth not exceeding Rs.25 Crores, as on last day of previous financial year. This is to certify that the paid-up equity capital of the company is Rs.24,50,000/- (Rs. Twenty-Four Lakh Fifty Thousand Only) which is less than Rs.10 Crores (Rs. Ten Crores) and Net worth is Rs.13,66,68,576/- (Rs. Thirteen Crores Sixty-Six Lakh Sixty-Eight Thousand Five Hundred Seventy-Six Only) which is less than Rs.25 Crores. (Rs. Twenty-Five Crores) as per the audited Balance sheet as at 31st March 2025, which is within the limit as prescribed in Regulation 15(2) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.</p>
Payment of Advance Income Tax	

39